

Calcium phosphate nanoparticles-based systems for siRNA delivery

Xiaochun Xu^{1,†}, Zehao Li^{1,†}, Xueqin Zhao¹, Lawrence Keen¹ and Xiangdong Kong^{1,2,*}

¹Institute of Biomaterials and Marine Biological Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China; ²College of Materials and Textiles, Zhejiang Sci-Tech University, Hangzhou 310018, China

†These authors contributed equally to this work.

*Correspondence address: Institute of Biomaterials and Marine Biological Resources, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China. Tel: +0086-0571-86843196; E-mail: kxd01@126.com

Received 29 October 2015; revised 11 January 2016; accepted on 19 January 2016

Abstract

Despite the enormous therapeutic potential of siRNA as a treatment strategy, the delivery is still a problem due to unfavorable biodistribution profiles and poor intracellular bioavailability. Calcium phosphate (CaP) co-precipitate has been used for nearly 40 years for *in vitro* transfection due to its non-toxic nature and simplicity of preparation. The surface charge of CaP will be tuned into positive by surface modification, which is important for siRNA loading and crossing cell membrane without enzymatic degradation. The new siRNA carrier system will also promote the siRNA escape from lysosome to achieve siRNA sustained delivery and high-efficiency silence. In this review, we focus on the current research activity in the development of CaP nanoparticles for siRNA delivery. These nanoparticles are mainly classified into lipid coated, polymer coated and various other types for discussion.

Keywords: calcium phosphate; siRNA; nanoparticles; delivery

Introduction

siRNA (small interfering RNA) is a short dsRNA (typically 20–27 bp), which is known for its ability to silence gene expression in a sequence specific manner (RNA interference) [1, 2]. siRNA is produced when long double-stranded RNA precursors are cleaved by the endonuclease dicer into smaller molecules, and then enter the RNA-induced silencing complex [3–6]. RNA interference was investigated for therapeutic applications after it was discovered in the 1990s [7]. If a disease-related gene could be silenced by RNA interference, then symptoms would be eliminated, therefore siRNA offers a new type to treat a wide variety of diseases [8–10]. However, the utilization of RNA interference in medical treatment currently has found a challenge in siRNA intracellular delivery. This is because of the polyanionic nature of siRNA that prevents efficient diffusion through cellular membranes [11, 12]. Moreover, free siRNA shows unfavorable pharmacokinetic profiles due to their rapid blood degradation and elimination within the cells or systems [13]. A feasible method of siRNA delivery is to look for an ideal carrier, which is safe, inexpensive as well as being easy to produce, and should protect siRNA from either premature enzymatic degradation by

avoiding opsonization and subsequent rapid clearance. The siRNA-loading carrier should be taken up by the target cell where it can release its cargo accurately [14, 15].

Various materials, most typically lipids, polymers and partial inorganic nanomaterials have been utilized in siRNA delivery system. The lipids are logical choice in siRNA delivery systems because the cell membrane is rich in lipids [16–18]. As a typical representative, polyethylenimine (PEI) has been commonly used as the standard for siRNA delivery because of its high cellular uptake and efficient endosomal escape [19–22]. However, lipids and polymers both have been found to have a toxic effect in cell lines [23, 24]. It was shown that inflammatory toxicity and liver toxicity occurred after systemic administration of lipid nanocarriers to mice [25, 26]. The toxicity of PEI partly comes from its limited biodegradability. When PEI molecules are released from polyplexes, free PEI molecules will interact with serum proteins and even red blood cell surfaces to form aggregates to adhere to tissue surfaces to cause acute cell damage [27, 28]. The inorganic nanomaterials used in the siRNA transport mostly include CaP nanoparticles [29–31], calcium carbonate [32, 33], gold nanoparticles [34–37], iron oxide [38, 39], carbon

nanotubes [40, 41]. However, the challenge to decrease the levels of cytotoxicity to a clinically viable standard is still concerned.

Calcium phosphate (CaP) was developed for the delivery of DNA nearly 40 years ago [42, 43] and siRNA in recent years [44]. As a similar element of bone and teeth, CaP shows negligible cytotoxicity for siRNA delivery due to its inherent biocompatibility and biodegradability [45, 46]. Besides, CaP can be internalized into cells via the endocytosis route and the dissolution of CaP in the acidic endosome, which helps siRNA release into the cytosol and silence specific genes. Although the use of CaP for siRNA has made a lot of progress, the application of CaP-siRNA in clinical therapy is far from satisfaction, mostly because of its physical instability and weak electropositivity. CaP can be rendered with suitable properties as an excellent siRNA carrier through different modification [47]. In this review, we will focus on the recent progress of CaP nanoparticles for siRNA delivery, which are classified into poly (ethylene glycol) (PEG) coated [48–50], lipid coated [51, 52], PEI [53, 54] modified and other various polymer types.

CaP Nanoparticles

Different polymorph of CaP, including hydroxyapatite (HAp), octacalcium phosphate (OCP) and amorphous calcium phosphate (ACP) can be synthesized by different regulation [55]. Zhao *et al.* [56] successfully prepared sericin regulated HAp and ACP in water. Moreover, bioinspired nano–micro structured-OCP was synthesized through mild electrochemical deposition method, which can be applied to hard tissue engineering [57].

As a siRNA carrier, CaP is able to target cancer cells accurately, condense the siRNA and release siRNA efficiently [48]. However, the main problems associated with CaP are its physical instability and low transfection efficiency that limit its therapeutic application [58, 59]. There is potential for further efforts to improve the stability and transfection efficiency by developing a new synthesis approach or combining CaP with other materials through different methods [60]. Therefore, different strategies have been evaluated to stabilize CaP particles and enhance transfection efficiency.

PEG-coated

PEG is used to modify CaP nanoparticles mainly because its hydrophilic and neutral features. It can help enhance the stability of compound, reduced protein adsorption and immunogenicity [61, 62]. Giger *et al.* [50] used PEGylated chelating agents (PEG-alendronate and PEG-inositol-pentakisphosphate) to prepare CaP nanoparticles through co-precipitation and found that CaP had stable enough properties to efficiently deliver siRNA *in vitro* (Fig. 1)[]. Moreover, the integration of PEG-block siRNA into CaP led to size-controllable hybrid nanoparticles, which facilitated the internalization of siRNA by cells [63]. PEG-functionalized bisphosphonate (PEG-bp) was used to prepare bp-stabilized CaP nanoparticles with the size of ~200 nm for gene delivery [64]. PEG-bp-CaP showed effective and sustained transfection ability to cells *in vitro* with low toxicity. Giger *et al.* [50] further used PEG-alendronate (PEG-ALE) to form PEG-ALE-CaP nanoparticles for siRNA delivery. PEG-ALE-CaP-siRNA exhibited a strong silencing effect *in vitro* at both the mRNA and protein levels. The cellular trafficking study showed that PEG-ALE-CaP-siRNA internalized into cells relied largely on the clathrin-dependent endocytosis. In addition, Giger *et al.* [50] obtained the similar conclusion that CaP nanoparticles stabilized with PEGylated chelators were mainly taken up into human prostatic

carcinoma (PC-3) cell by clathrin-dependent endocytosis. Zhang *et al.* [65] utilized electrostatic interactions between the anionic charges of siRNA and the cationic charges on the PEGylated CaP crystal surface to prepare CaP/siRNA nanoparticles with sizes between 90 and 200 nm, resulting in the nanoparticles showing significant gene silencing efficiency on cultured cells.

The growth of CaP can be inhibited after introducing PEG on the surface of CaP crystal. Kataoka's [66] group has investigated the hybrid polymer CaP nanoparticles for gene delivery for one decade. First, they used PEG-block-poly (aspartic acid) (PEG-PAA) to prevent precipitation of CaP crystals. Between the CaP core and PEG-PAA shell siRNA was surrounded by electrostatic attraction, and the core-shell nanoparticles presented efficient transfection [29]. They also verified that CaP nanoparticles are taken up by the cells through an energy-dependent endocytotic pathway. On further research, they found it was hard to increase the siRNA entrapment with a small size of particles, because siRNA and PEG-b-polyanion were competitively bound to the CaP crystal [67]. To overcome the challenge, they firstly integrated siRNA into block copolymers via a disulfide bond to form PEG-SS-siRNA conjugates [63], and demonstrated that the conjugate of siRNA with PEG via a disulfide linkage regulated the crystal growth of CaP and yielded a monodispersed nanocomposite. The prepared PEG-SS-siRNA/CaP exhibited prolonged stability in serum containing medium and substantial RNAi efficacy.

The charge-conversional polymer (CCP), of which anionic functional groups could be converted to cationic groups in an endosomal acidic condition for facilitated endosomal escape. It shows high stability at neutral and basic pHs but it becomes cleavable at acidic pH to release the cargo [68]. Kataoka's group presented a hybrid nanocarrier system composed of CaP (comprising the block copolymer of PEG) and CCP (as a siRNA vehicle). The CaP in these nanoparticles formed a stable core to incorporate siRNA and PEG-CCP. The synthesized PEG-CCP is a non-toxic endosomal escaping unit, which induces endosomal membrane destabilization, and rapid escape of siRNA. The nanocarrier possess excellent siRNA-loading efficiency (~80% of dose), and efficiently induced vascular endothelial growth factor (VEGF) mRNA knockdown (~80%) in pancreatic cancer cells (Panc-1) [69]. Pittella *et al.* [70] further prepared PEG-CCP/siRNA/CaP hybrid nanoparticles for systemic delivery of siRNA to solid tumors. They found that the nanoparticles showed high gene silencing efficiency in cultured pancreatic cancer cells (BxPC3) *in vitro* and significant reduction in the subcutaneous BxPC3 tumor growth, very consistent with the significant VEGF gene silencing (~68%) in the tumor. To further evaluate the clinical application of siRNA in cancer therapy, they developed safe and efficient nanocarrier PEG-CCP/CaP hybrid micelles to systemically deliver siRNA and studied the efficacy of PEG-CCP/siRNA/CaP in spontaneous bioluminescent pancreatic tumors from transgenic mice (Fig. 2). They found that intravenous injection of PEG-CCP/CaP-siRNA significantly reduced the luciferase-based luminescent signal from the spontaneous pancreatic tumors with no significant changes in hematological parameters in mice.

Improving the transfection efficiency of nanoparticles-based medicine in clinical therapy has been limited by the low effectiveness of nanoparticles across the cell membrane. Endocytosis has been reported to play a key role in the internalization of CaP [71]. For example, a nanoparticle coated with PEG-ALE was found to use clathrin-dependent endocytosis [50]. Tobin *et al.* [72] used PEGylated triple-shell CaP nanoparticles to absorb therapeutic siRNA and ultra-low levels of doxorubicin, and found that the




Figure 1. The CaP NPs coated with PEG-ALE. (Reprinted with permission from reference [50].)

nanoparticles could preferentially localize to tumor *in vivo*, be internalized by tumor cells in an increasing capacity, effectively deliver siRNA to cause significant decrease of XIAP and inhibit the tumor growth effectively. Moreover, a critical ability of the nanoparticles was to induce the apoptosis of cancer cells while avoiding normal tissue.

As promising PEGylated chelators, bps or inositol pentakisphosphate represent stabilizing agents for calcium phosphate nanoparticles. Phospholipid-methoxy PEG (PS-mPEG), whose main composition is phosphatidylserine—a main component of cell membrane, has good biocompatibility and is easy to adhere to the cell membrane. Wang *et al.* [73] reported siRNA-loaded PS-mPEG/CaP nanospheres that had good entrapment efficiency of siRNA of up to 92.86%. The nanospheres could carry siRNA into the cells then induce cell apoptosis effectively *in vitro* and carry siRNA into the tumor tissue effectively *in vivo*.

Liposome-coated

Several research groups have successfully used lipids to inhibit the rapid growth of CaP particles for gene delivery with negligible toxicity. Though cationic liposomes are widely used transfection vectors, due to their notable efficiency [74], the cytotoxicity of liposomes makes it difficult in clinical cases [75, 76]. Khatri *et al.* [44] used liposomes composed of a neutral lipid Dipalmitoyl-sn-glycero-3-phosphocholine, a fusogenic lipid dioleoyl-sn-glycero-3-phosphoethanolamine, a PEGylated lipid (DSPE-mPEG 2000) and cholesterol to entrap CaP and siRNA. The mixtures were further grafted with cRGD to achieve targeting potential for cancer cells. The final nanoparticles had a size below 150 nm, around 80% of siRNA entrapped and higher transfection efficiency than Lipofectamine 2000. Developed liposomal-CaP showed effective protection of siRNA against serum nucleases, excellent stability against electrolyte induced flocculation, and effective target gene silencing up to $24.1 \pm 3.4\%$.

As Figure 3 shows, Huang and his group undertook an in-depth study on CaP modified with liposome for siRNA delivery for many years. At the beginning, they developed lipid-coated calcium phosphate (LCP) nanoparticles, which they called LCP-I afterwards, for efficient delivery of siRNA to a xenograft tumor model by intravenous administration [77]. On the previous formulation, they designed a core/shell nanoparticle structure which was named liposome-polycation-DNA (LPD) [78]. LPD showed a striking success in delivering siRNA, but the release of siRNA into the cytoplasm still needed improvement. They replaced the core of LPD with the acid-sensitive CaP and prepared LCP-I using water-in-oil microemulsions in which siRNA was entrapped. After further modifying LCP-I with a PEG linker, they found that the LCP nanoparticles had excellent siRNA delivery activity *in vitro* and in a xenograft tumor model. To improve the targeted delivery of LCP-I, they grafted the nanoparticles with PEG and anisamide (AA) ligand on the surface [79]. The improved LCP-I exhibited a 40 nm particle size and 91% siRNA encapsulation efficiency. Further therapeutic experiments revealed, siRNA formulated in LCP-I significantly increased oncogenes silencing and reduced lung metastases (similar to 70–80%). By studying the acid sensibility of LCP-I and imaging of intracellular calcium release, they found a new cargo release mechanism from the endosome that differs from the well reported proton sponge effect [80] and ion-pair effect [81]. The CaP core was dissolved at low pH, allowing dissolved calcium and phosphate ions to increase the osmotic pressure and resulted in the swelling of the endosome, following this, the endosome burst releasing the siRNA cargo into cytoplasm [77].

Dioleoylphosphatidic acid (DOPA), an anionic lipid, was employed as the inner leaflet lipid to coat the CaP cores, which entraps the siRNA. As Figure 4 shows, researchers further developed new nanoparticles, named LCP-II [52]. The outer leaflet lipid used a suitable neutral or cationic lipid to form an asymmetric lipid bilayer structure and was covered by a PEG-phospholipid conjugate. The final nanoparticles were named LCP-II with a diameter of 25–40 nm and a hollow core (Fig. 4). LCP-II could release more siRNA to the




Figure 2. The preparation of hybrid micelles with PEG-CCP, siRNA, and CaP (A). Chemical structure of PEG-PAsp (DET-Aco), termed PEG-CCP (B). The cellular delivery of siRNA by PEG-CCP/CaP hybridmicelles (C). (Reprinted with permission from ref. [30].)

cytoplasm than LPD formulation, leading to a significant (~ 40 -fold *in vitro* and ~ 4 -fold *in vivo*) improvement in siRNA delivery.

To improve the process of LCP for combinational delivery of associated drugs, a biodegradable and amorphous core of CaP was used to encapsulate the therapeutic agents. The CaP core was coated with an asymmetrical lipid bilayer: the inner leaflet consisted of DOPA the outer leaflet was a cationic lipid DOTAP and a helper lipid cholesterol [82]. The nanoparticles were further modified with PEG phospholipid (DSPE-PEG)

and AA grafted onto the surface. The LCP nanoparticles could co-deliver the chemotherapeutic drug gemcitabine monophosphate (GMP) and siRNA specific to the undruggable cMyc oncogene (cMyc siRNA) into the cytoplasm and effectively induce the apoptosis of tumor cells and the anti-tumor activity in both subcutaneous and orthotopic models of aggressive non-small-cell lung cancer over either cMyc siRNA or GMP therapy alone. In their latest research, they produced a new optimized LCP NP delivery system which could improve siRNA in cellular accumulation. Compared




Figure 3. The schematic illustration of the process for LCP nanoparticles. (Reprinted with permission from reference [77].)

with Oligofectamine, a commercial RNA transfection reagent, it significantly inhibited the growth of human breast cancer cells *in vitro* [83].

PEI modified

PEI is well known as a transfection reagent, but its cytotoxicity limits its further clinical application for the delivery of gene or drug treatment [84–86]. Devarasu *et al.* [87] described hybrid CaP nanoparticles, built by alternate deposition of siRNA and modified with PEI ($\text{CPnp}(\text{siRNA}/\text{PEI})_2$) (Fig. 5). The CaP nanoparticles showed an efficient gene silencing effect reached up to 95% in a luciferase expressing cells *in vitro* and a tumor xenograft mouse model *in vivo*. Interestingly, they found the grafting of a sugar moiety on PEI could modify the *in vivo* biodistribution of the particles without modifying the size, stability and *in vitro* efficiency.

Other polymer coated

Besides the PEG and liposome coating mentioned above, Lee *et al.* [88] used DOPA (3, 4-dihydroxy-L-phenylalanine) modified chitosan to prevent further growth of CaP crystal by adsorption on to the crystal surface. Due to this, the prepared CaP/siRNA/DOPA-chitosan significantly increased the serum stability of siRNA, showing high cellular uptake efficiency, and had notable silencing effect of special gene. In addition, Choi *et al.* [89] developed a stable CaP nanocarrier system which could enhance intracellular uptake vastly by adding the highly cationic, glutamine-conjugated oligochitosan (Gln-OChi). CaP/siRNA//Gln-OChi was prepared to target noggin, a bone morphogenetic protein antagonist, and the osteogenic bioactivity of CaP/siRNA//Gln-OChi was further confirmed in 3D environments. Kozlova *et al.* [90] coated CaP with a shell of silica and covalently functionalized by silanization for covalent attachment of molecules like dyes or antibodies allowing siRNA to be incorporated




Figure 4. The schematic illustration for the preparation of LCP-II NP and the structure of DOPA (A). TEM image of CaP cores coated with DOPA (B). Hypothesis of the CaP core growth (C). TEM images of LCP-II NPs coated with DOTAP and DSPE-PEG without (D) and with (E) negative staining. Arrows in (E) show lipid bilayer surrounding the CaP core. (Reprinted with permission from references [52].)




Figure 5. The schematic illustration of the process for CPnp (siRNA/PEI)₂.

into the cavity between the CaP surface and the outer silica shell. Then the cellular uptake of CaP nanoparticles was demonstrated on HeLa and MG-63 cell lines, and they found that the functionalization of CaP with a dendritic cell-specific antibody (CD11c) led to a cell-specific targeting *in vivo*.

To improve the diagnostic efficacy of the cargo molecules, Singh *et al.* [91] reported a biocompatible CaP-based delivery system with in situ imaging capacity. The CaP nanoparticles (formed as nanorods, 40 × 10 nm), prepared by a citrate-involved sol-gel process, showed a strong blue emission at 427 nm under fluorescence

microscopy, and had excellent cell viability (over 90% for both osteoblasts and osteoclasts). The siRNA-loaded CaP exhibited sustainable siRNA release over 5 days, excellent osteoblastic uptake (96% efficiency) and gene-silencing effect, while preserving intracellular fluorescence signals. Qin *et al.* [92] prepared Pluronic F127/CaP hybrid nanoparticles (F127/CaP) (120–210 nm in diameter) by a facile room temperature method and employed them as carriers to deliver siRNA to silence tumor cell. F127/CaP had effective siRNA encapsulating efficiency up to 91.5 wt % with a loading content of 6.5 wt. %, and exhibited higher gene inhibition efficiency than traditional CaP transfection method.

Conclusion

A wide variety of CaP nanoparticles have been developed for efficient siRNA delivery by coating suitable PEG, liposome or other polymer to CaP crystals. Generally, PEG-coated CaP is more stable than other modifications due to the colloidal stability of PEG, while liposome-coated CaP has better a transfection efficiency relying upon the cationic characteristics of the lipids. We can compare coating CaP with other modifications, such as chitosan or PEI, which provide a broader range of applications in different fields of siRNA delivery. To further improve the capability of CaP for siRNA, combinations of different coatings such as PEG and PEI have gained more attention and rapid development. Hopefully, this can lead to improvements in the inadequacy of CaP-siRNA *in vitro* and *in vivo* and provide a novel carrier system to target specific diseases, especially cancer.

Funding

This work was supported by Grants from the National Natural Science Foundation of China (51272236, 51002139), and the Program for 521 Excellent Talents of Zhejiang Sci-Tech University.

Conflict of interest statement. None declared.

References

- Kleinman ME, Kaneko H, Cho WG. *et al.* Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. *Mol Ther* 2012;20:101–8.
- Bora RS, Gupta D, Mukkur TKS. *et al.* RNA interference therapeutics for cancer: challenges and opportunities (review). *Mol Med Rep* 2012;6:9–15.
- Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. *J Nanomater* 2011;2011:16247–56.
- Iwasaki S, Sasaki HM, Sakaguchi Y. *et al.* Defining fundamental steps in the assembly of the drosophila RNAi enzyme complex. *Nature* 2015;521:533–6.
- Liu Y, Karg M, Herrera-Carrillo E *et al.* Towards antiviral shRNAs based on the agoshRNA design. *Plos One* 2015;10:e0128618
- Takahashi T, Zenno S, Ishibashi O. *et al.* Interactions between the non-seed region of siRNA and RNA-binding RLC/RISC proteins, Ago and TRBP, in mammalian cells. *Nucleic Acids Res* 2014;42:5256–69.
- Fire A, Xu S, Montgomery MK. *et al.* Potent and specific genetic interference by double-stranded RNA in *caenorhabditis elegans*. *Nature* 1998;391:806–11.
- Wang Z, Liu G, Zheng H. *et al.* Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. *Biotechnol Adv* 2014;32:831–43.
- Schiffelers R, Ansari A, Xu J. *et al.* Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. *Nucleic Acids Res* 2004;32:e149
- Judge A, Robbins M, Tavakoli I. *et al.* Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. *J Clin Invest* 2009;119:661–73.
- Breton M, Delemotte L, Silve A. *et al.* Transport of siRNA through lipid membranes driven by nanosecond electric pulses: An experimental and computational study. *J Am Chem Soc* 2012;134:13938–41.
- Stoppiani E, Bassi I, Dotti S. *et al.* Expression of a single siRNA against a conserved region of NP gene strongly inhibits *in vitro* replication of different influenza A virus strains of avian and swine origin. *Antivir Res* 2015;120:16–22.
- Chen B, Xu W, Pan R. *et al.* Design and characterization of a new peptide vector for short interfering RNA delivery. *J Nanobiotech* 2015;13:39
- Juliano R, Alam MR, Dixit V. *et al.* Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. *Nucleic Acids Res* 2008;36:4158–71.
- Wang J, Lu Z, Wientjes MG. *et al.* Delivery of siRNA therapeutics: barriers and carriers. *Aaps J* 2010;12:492–503.
- Alhakamy NA, Elandaloussi I, Ghazvini S. *et al.* Effect of lipid headgroup charge and pH on the stability and membrane insertion potential of calcium condensed gene complexes. *Langmuir* 2015;31:4232–45.
- Egawa J, Pearn ML, Lemkuil BP. *et al.* Membrane/lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function. *J Physiol* 2015. doi: 10.1113/JP270590.
- Bakalis E, Hofinger S, Venturini A. *et al.* Crossover of two power laws in the anomalous diffusion of a two lipid membrane. *J Chem Phys* 2015;142:215102.
- Nicoli E, Syga MI, Bosetti M. *et al.* Enhanced gene silencing through human serum albumin-mediated delivery of polyethylenimine-siRNA polyplexes. *Plos One* 2015;10:e0122581.
- Huang H, Yu H, Tang G. *et al.* Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. *Biomaterials* 2010;31:1830–8.
- Schafer J, Hobel S, Bakowsky U. *et al.* Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. *Biomaterials* 2010;31:6892–900.
- Ma Y, Yang Y. Delivery of DNA-based cancer vaccine with polyethylenimine. *Eur J Pharm Sci* 2010;40:75–83.
- Xue H, Liu S, Wong H. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. *Nanomedicine* 2014;9:295–312.
- Li J, He Y, Li W. *et al.* A novel polymer-lipid hybrid nanoparticle for efficient nonviral gene delivery. *Acta Pharmacol Sin* 2010;31:509–14.
- Tousignant JD, AL G, LA I. *et al.* Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. *Hum Gene Ther* 2000;11:2493–513.
- Schlegel A, Bigey P, Dhotel H. *et al.* Reduced *in vitro* and *in vivo* toxicity of siRNA-lipoplexes with addition of polyglutamate. *J Control Release* 2013;165:1–8.
- Singha K, Namung R, Kim WJ. Polymers in small-interfering RNA delivery. *Nucleic Acid Ther* 2011;21:133–47.
- Godbey WT, Wu K, Mikos AG. Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. *Biomaterials* 2001;22:471–80.
- Kakizawa Y, Furukawa S, Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. *J Control Release* 2004;97:345–56.
- Pittella F, Cabral H, Maeda Y. *et al.* Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. *J Control Release* 2014;178:18–24.
- Neuhaus B, Frede A, Westendorf AM. *et al.* Gene silencing of the pro-inflammatory cytokine TNF- α with siRNA delivered by calcium phosphate nanoparticles, quantified by different methods. *J Mater Chem B* 2015;3:7186–93.
- Kong X, Xu S, Wang X. *et al.* Calcium carbonate microparticles used as a gene vector for delivering p53 gene into cancer cells. *J Biomed Mater Res* 2012;100:2312–8.
- Zhao RB, Han HF, Ding S. *et al.* Effect of silk sericin on morphology and structure of calcium carbonate crystal. *Front Mater Sci* 2013;7:177–83.

34. Shirazi AN, Paquin KL, Howlett NG. *et al.* Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. *Molecules* 2014;19:13319–31.
35. Ghiassian S, Gobbo P, Workentin MS. Water-soluble maleimide-modified gold nanoparticles (AuNPs) as a platform for cycloaddition reactions. *Eur J Org Chem* 2015;5438–47.
36. Messersmith RE, Nusz GJ, Reed SM. Using the localized surface plasmon resonance of gold nanoparticles to monitor lipid membrane assembly and protein binding. *J Phys Chem C* 2013;117:26725–33.
37. Jeong S, Choi SY, Park J. *et al.* Low-toxicity chitosan gold nanoparticles for small hairpin RNA delivery in human lung adenocarcinoma cells. *J Mater Chem* 2011;21:13853–9.
38. Zhang D, Wang J, Wang Z. *et al.* Polyethyleneimine-coated Fe₃O₄ nanoparticles for efficient siRNA delivery to human mesenchymal stem cells derived from different tissues. *Sci Adv Mater* 2015;7:1058–64.
39. Li T, Shen X, Chen Y. *et al.* Polyetherimide-grafted Fe₃O₄@SiO₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging. *Int J Nanomed* 2015;10:4279–91.
40. Liu Z, Winters M, Holodniy M. *et al.* siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. *Angew Chem Int Edit* 2007;46:2023–7.
41. Herrero MA, Toma FM, Al-Jamal KT. *et al.* Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery. *J Am Chem Soc* 2009;131:9843–8.
42. Yen TS, Wang Y, Seto E. DNA transfection into suspension cell lines with a modified calcium phosphate precipitate method. *Biotechniques* 1988;6:413–6.
43. Zhao R, Yang X, Han H. *et al.* Research development of the transfection efficiency and targeting of hydroxyapatite nanoparticles based gene vectors. *Materials Rev.* 2014;28:124–8.
44. Khatri N, Baradia D, Vhora I. *et al.* cRGD grafted liposomes containing inorganic nano-precipitate complexed siRNA for intracellular delivery in cancer cells. *J Control Release* 2014;182:45–57.
45. Cohen B, Panker M, Zuckerman E. *et al.* Effect of calcium phosphate-based fillers on the structure and bonding strength of novel gelatin-alginate bioadhesives. *J Biomater Appl* 2014;28:1366–75.
46. Sharma S, Verma A, Teja BV. *et al.* An insight into functionalized calcium based inorganic nanomaterials in biomedicine: trends and transitions. *Colloid Surface B* 2015;133:120–39.
47. Zhao X, Zhu Y, Chen F. *et al.* Calcium phosphate hybrid nanoparticles: self-assembly formation, characterization, and application as an anticancer drug nanocarrier. *Chem Asian J* 2013;8:1306–12.
48. Xie Y, Qiao H, Su Z. *et al.* PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy. *Biomaterials* 2014;35:7978–91.
49. Maeda Y, Pittella F, Nomoto T. *et al.* Fine-tuning of charge-conversion polymer structure for efficient endosomal escape of siRNA-loaded calcium phosphate hybrid micelles. *Macromol Rapid Comm* 2014;35:1211–5.
50. Giger EV, Castagner B, Raikonen J. *et al.* siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators. *Adv Healthc Mater* 2013;2:134–44.
51. Haynes MT, Huang L. Lipid-coated calcium phosphate nanoparticles for nonviral gene therapy. *Adv Genet* 2014;88:205–29.
52. Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. *J Control Release* 2012;158:108–14.
53. Ito T, Koyama Y, Otsuka M. Preparation of calcium phosphate nanocapsule including deoxyribonucleic acid-polyethyleneimine-hyaluronic acid ternary complex for durable gene delivery. *J Pharm Sci* 2014;103:179–84.
54. Ashokan A, Gowd GS, Somasundaram VH. *et al.* Multifunctional calcium phosphate nano-contrast agent for combined nuclear, magnetic and near-infrared *in vivo* imaging. *Biomaterials* 2013;34:7143–57.
55. Montastruc L, Azzaro-Pantel C, Biscans B. *et al.* A thermochemical approach for calcium phosphate precipitation modeling in a pellet reactor. *Chem Eng J* 2003;94:41–50.
56. Zhao R, Yang X, Chen C. *et al.* The anti-tumor effect of p53 gene-loaded hydroxyapatite nanoparticles *in vitro* and *in vivo*. *J Nanopart Res* 2014;16:2353
57. Yang Y, Wang H, Yan FY. *et al.* Bioinspired porous octacalcium phosphate/silk fibroin composite coating materials prepared by electrochemical deposition. *ACS Appl Mater Inter* 2015;7:5634–42.
58. Suzuki T, Yamamoto T, Toriyama M. *et al.* Surface instability of calcium phosphate ceramics in tissue culture medium and the effect on adhesion and growth of anchorage-dependent animal cells. *J Biomed Mater Res* 1997;34:507–17.
59. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. *Expert Rev Mol Diagn* 2005;5:893–905.
60. Bhakta G, Shrivastava A, Maitra A. Magnesium phosphate nanoparticles can be efficiently used *in vitro* and *in vivo* as non-viral vectors for targeted gene delivery. *J Biomed Nanotechnol* 2009;5:106–14.
61. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. *Adv Drug Deliver Rev* 2001;47:113–31.
62. Kakizawa Y, Furukawa S, Ishii A. *et al.* Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block anioner. *J Control Release* 2006;111:368–70.
63. Zhang M, Ishii A, Nishiyama N. *et al.* PEGylated calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA delivery. *Adv Mater* 2009;21:3520–5.
64. Giger EV, Puigmartí-Luis J, Schlatter R. *et al.* Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles. *J Control Release* 2011;150:87–93.
65. Zhang M, Lin W, Lin B. *et al.* Facile preparation of calcium phosphate nanoparticles for siRNA delivery: Effect of synthesis conditions on physicochemical and biological properties. *J Nanosci Nanotechnol* 2012;12:9029–36.
66. Kakizawa Y, Kataoka K. Block copolymer self-assembly into monodisperse nanoparticles with hybrid core of antisense DNA and calcium phosphate. *Langmuir* 2002;18:4539–43.
67. Kakizawa Y, Miyata K, Furukawa S. *et al.* Size-controlled formation of a calcium phosphate-based organic-inorganic hybrid vector for gene delivery using poly (ethylene glycol)-block-poly (aspartic acid). *Adv Mater* 2004;16:699–702.
68. Lee Y, Fukushima S, Bae Y. *et al.* A protein nanocarrier from charge-conversion polymer in response to endosomal pH. *J Am Chem Soc* 2007;129:5362–3.
69. Pittella F, Zhang M, Lee Y. *et al.* Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. *Biomaterials* 2011;32:3106–14.
70. Pittella F, Miyata K, Maeda Y. *et al.* Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles. *J Control Release* 2012;161:868–74.
71. Sokolova V, Kozlova D, Knuschke T. *et al.* Mechanism of the uptake of cationic and anionic calcium phosphate nanoparticles by cells. *Acta Biomater* 2013;9:7527–35.
72. Tobin LA, Xie Y, Tsokos M. *et al.* PEGylated siRNA-loaded calcium phosphate nanoparticle-driven amplification of cancer cell internalization *in vivo*. *Biomaterials* 2013;34:2980–90.
73. Wang Q, Qin L, Sun Y. *et al.* Study of siRNA-loaded PS-mPEG/CaP nanospheres on lung cancer. *J Nanopart Res* 2014;16:1–9.
74. Lasic D, Templeton N. Liposomes in gene therapy. *Adv Drug Deliver Rev* 1996;20:221–66.
75. Csuk R, Barthel A, Kluge R. *et al.* Synthesis, cytotoxicity and liposome preparation of 28-acetylenic betulin derivatives. *Bioorgan Med Chem* 2010;18:7252–9.
76. Yao H, Jin H, Wu K. *et al.* Impact of polyamidoamine dendrimer liposome on the cellular uptake and cytotoxicity of colonic cancer cells. *Zhonghua Wai Ke Za Zhi* 2010;48:1815–8.
77. Li J, Chen Y, Tseng YC. *et al.* Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. *J Control Release* 2010;142:416–21.

78. Chen Y, Sen J, Bathula SR. *et al.* Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. *Mol Pharm* 2009;6:696–705.
79. Yang Y, Li J, Liu F. *et al.* Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. *Mol Ther* 2011;20:609–15.
80. Thomas M, Klibanov AM. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. *P Natl Acad Sci* 2002;99:14640–5.
81. Hafez I, Maurer N, Cullis P. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. *Gene Ther* 2001;8:1188–96.
82. Zhang Y, Peng L, Mumper RJ. *et al.* Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. *Biomaterials* 2013;34:8459–68.
83. Tang J, Li L, Howard CB. *et al.* Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced *in vitro* gene delivery to breast cancer cells. *J Mater Chem B* 2015;3:6805–12.
84. Nguyen H, Lemieux P, Vinogradov S. *et al.* Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. *Gene Ther* 2000;7:126–38.
85. Brunot C, Ponsonnet L, Lagneau C. *et al.* Cytotoxicity of polyethylenimine (PEI), precursor base layer of polyelectrolyte multilayer films. *Biomaterials* 2007;28:632–40.
86. Yang HJ, Feng P, Wang L. *et al.* Caveolin-1 mediates gene transfer and cytotoxicity of polyethylenimine in mammalian cell lines. *Mol Cell Biochem* 2015;402:203–11.
87. Devarasu T, Saad R, Ouadi A. *et al.* Potent calcium phosphate nanoparticle surface coating for *in vitro* and *in vivo* siRNA delivery: a step toward multifunctional nanovectors. *J Mater Chem B* 2013;1:4692–700.
88. Lee K, Oh MH, Lee MS. *et al.* Stabilized calcium phosphate nano-aggregates using a dopa-chitosan conjugate for gene delivery. *Int J Pharm* 2013;445:196–202.
89. Choi BY, Cui ZK, Kim S. *et al.* Glutamine-chitosan modified calcium phosphate nanoparticles for efficient siRNA delivery and osteogenic differentiation. *J Mater Chem B* 2015;3:6448–55.
90. Kozlova D, Chernousova S, Knuschke T. *et al.* Cell targeting by antibody-functionalized calcium phosphate nanoparticles. *J Mater Chem* 2012;22:396–404.
91. Singh RK, Kim T-H, Patel KD. *et al.* Development of biocompatible apatite nanorod-based drug-delivery system with *in situ* fluorescence imaging capacity. *J Mater Chem B* 2014;2:2039–50.
92. Qin L, Sun Y, Liu P. *et al.* F127/calcium phosphate hybrid nanoparticles: a promising vector for improving siRNA delivery and gene silencing. *J Biomat Sci-Polym E* 2013;24:1757–66.